Drug Profile
Salmeterol inhalation powder - Boehringer Ingelheim
Alternative Names: Salmeterol xinafoate inhalation powder - Boehringer IngelheimLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 24 Sep 2014 Discontinued - Phase-II for Chronic obstructive pulmonary disease in Germany (Inhalation) prior to September 2014